2024
The incidence, providers involved, and patient factors associated with diagnosis of specific lumbar spine pathology subsequent an initial nonspecific low back pain diagnosis
Seddio A, Jabbouri S, Gouzoulis M, Sanchez J, Day W, Varthi A, Rubio D, Grauer J. The incidence, providers involved, and patient factors associated with diagnosis of specific lumbar spine pathology subsequent an initial nonspecific low back pain diagnosis. The Spine Journal 2024, 25: 688-695. PMID: 39505011, DOI: 10.1016/j.spinee.2024.10.008.Peer-Reviewed Original ResearchLow back painPrimary care providersLow back pain diagnosisNS-LBPInternational Classification of DiseasesLumbar spine pathologyHistory of cancerSpecialty providersOpioid use disorderNonspecific low back painSpine pathologyBack pain diagnosisPCP providersFactors associated with diagnosisClassification of DiseasesUse disorderLBP managementLBP symptomsNational administrative databaseCare providersBack painFamily medicineAdult patientsProvider specialtyPain diagnosisAnterior cervical decompression and fusion at one and two levels: trends and factors associated with structural allograft versus synthetic cages
Kim L, Grauer J. Anterior cervical decompression and fusion at one and two levels: trends and factors associated with structural allograft versus synthetic cages. North American Spine Society Journal (NASSJ) 2024, 17: 100310. PMID: 38390524, PMCID: PMC10882181, DOI: 10.1016/j.xnsj.2024.100310.Peer-Reviewed Original ResearchCage useAnterior cervical decompressionAnterior cervical discectomyStructural allograftSynthetic cageLevel ACDFCervical decompressionACDF casesCervical discectomyClinical predictorsAdult patientsClinical factorsACDFAnterior plateFemale sexImplant choiceMultivariate analysisAllograftProvider specialtyCare algorithmOlder ageDecompressionNon-clinical
2023
Longitudinal Care Patterns and Utilization Among Patients With New-Onset Neck Pain by Initial Provider Specialty
Fenton J, Fang S, Ray M, Kennedy J, Padilla K, Amundson R, Elton D, Haldeman S, Lisi A, Sico J, Wayne P, Romano P. Longitudinal Care Patterns and Utilization Among Patients With New-Onset Neck Pain by Initial Provider Specialty. Spine 2023, 48: 1409-1418. PMID: 37526092, DOI: 10.1097/brs.0000000000004781.Peer-Reviewed Original ResearchConceptsNeck painProvider specialtyTherapeutic interventionsCare patternsPain visitsInitial visitOptum Labs Data WarehouseDiagnostic imagingAcute back painAcute neck painPlurality of patientsRetrospective cohort studyElectronic health record dataLarge national cohortInvasive therapeutic interventionsHealth record dataCohort studyMajor surgeryBack painOutpatient visitsNational cohortPrimary careTherapeutic injectionsEmergency physiciansBACKGROUND DATA
2021
Cement Augmentation of Vertebral Compression Fractures May Be Safely Considered in the Very Elderly
Galivanche AR, Toombs C, Adrados M, David WB, Malpani R, Saifi C, Whang PG, Grauer JN, Varthi AG. Cement Augmentation of Vertebral Compression Fractures May Be Safely Considered in the Very Elderly. Neurospine 2021, 18: 226-233. PMID: 33819949, PMCID: PMC8021820, DOI: 10.14245/ns.2040620.310.Peer-Reviewed Original ResearchVertebral compression fracturesAdverse eventsCompression fracturesCement augmentationAge categoriesNational Surgical Quality Improvement Program databaseInpatient/outpatient statusQuality Improvement Program databaseProcedural variablesMinor adverse eventsImprovement Program databaseSerious adverse eventsMultivariate logistic regressionYear old cohortPeriprocedure complicationsOlder patientsComorbidity statusOutpatient statusRetrospective reviewAdverse outcomesGeriatric populationProcedure typeProgram databaseProvider specialtyChi-square analysis
2020
Factors influencing palliative care referral for hospitalised patients with heart failure: an exploratory, randomised, multi-institutional survey of hospitalists and cardiologists
Abedini NC, Guo G, Hummel SL, Bozaan D, Beasley M, Cowger J, Chopra V. Factors influencing palliative care referral for hospitalised patients with heart failure: an exploratory, randomised, multi-institutional survey of hospitalists and cardiologists. BMJ Open 2020, 10: e040857. PMID: 33323440, PMCID: PMC7745336, DOI: 10.1136/bmjopen-2020-040857.Peer-Reviewed Original ResearchConceptsPalliative care referralAdvanced heart failureHeart failureOutpatient cardiologistCare referralProvider specialtyReferral decisionsAcute heart failure exacerbationPredictive marginsAdvance care planning documentationMichigan chapterPrior hospital admissionsHeart failure exacerbationAcute renal failureInpatient palliative carePalliative care deliveryCare planning documentationPalliative care guidelinesNumber of patientsAdvance care planningRenal failureSecondary outcomesHospital admissionPrimary outcomeIllness severity
2019
Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer.
Caram M, Wang S, Tsao P, Griggs J, Miller D, Hollenbeck B, Lin P, Mukherjee B. Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer. Urology Practice 2019, 6: 234-242. PMID: 31276025, PMCID: PMC6605774, DOI: 10.1097/upj.0000000000000020.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen signaling inhibitorsAdvanced prostate cancerFirst-line treatmentProstate cancerSystemic treatment of advanced prostate cancerDatabase of commercially insured patientsTreatment of advanced prostate cancerCastration-resistant prostate cancerSignaling inhibitorsPre-existing heart failureImproved overall survivalTreatment of menCommercially insured patientsSipuleucel-TRadium-223Overall survivalSystemic treatmentTreatment patternsNovel therapiesMedical oncologistsHeart failureMultivariate analysisProvider specialtyDocetaxel
2018
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma
Kaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalBarcelona Clinic Liver Cancer (BCLC) systemManagement of HCCVeterans Health Administration hospitalsRetrospective cohort studyFirst-line therapySimilar survival outcomesChild-TurcottePugh scoreComorbidity indexChart abstractionCohort studySurvival benefitSystemic therapyBCLC stagePrimary outcomePrescriber typeSurvival outcomesAdministration HospitalMultivariable modelProvider specialtyCancer stagingHCC diagnosis
2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. JCO Oncology Practice 2017, 13: jop.2016.020206. PMID: 28628393, PMCID: PMC5555032, DOI: 10.1200/jop.2016.020206.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerHospital referral regionsProstate cancerMetastatic castration-resistant prostate cancer treatmentCastration-resistant prostate cancerProvider specialtyAdvanced prostate cancerMedicare Part DProstate cancer incidenceFood and Drug AdministrationMinority of providersYears of ageEnzalutamide prescriptionsMultilevel regression modelsMedicare Part D dataPart DEnzalutamideAbirateroneMedical oncologistsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceWorkforce densityEarly national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D. Journal Of Clinical Oncology 2017, 35: 35-35. DOI: 10.1200/jco.2017.35.8_suppl.35.Peer-Reviewed Original ResearchAdvanced prostate cancerHospital referral regionsProstate cancerProvider specialtyAdvanced prostate cancer treatmentProstate cancer incidenceProstate cancer treatmentMedicare Part DEnzalutamide prescriptionsFood & Drug AdministrationMedicare Part D dataEnzalutamideMinority of providersAbirateroneMedical oncologistsOral medicationsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceDrug AdministrationCancer treatmentMultilevel regression modelsPart D
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply